Scott Kinlay, Ph.D., M.B.,B.S.
This page shows the publications Scott Kinlay has written about Anticholesteremic Agents.
Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007 May 22; 49(20):2003-9.
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004 Jul 27; 110(4):386-91.
Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol. 2003 Feb 20; 91(4A):9B-13B.
Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol. 1996 Dec; 7(6):389-97.
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009 Jun 09; 53(23):2186-96.
Vascular basis for the treatment of myocardial ischemia study: trial design and baseline characteristics. Am Heart J. 2004 May; 147(5):875-82.
Treating ambulatory ischemia in coronary disease by manipulating the cell biology of atherosclerosis. Curr Atheroscler Rep. 2000 Jul; 2(4):321-6.
Effect of lipid-lowering therapy on vasomotion and endothelial function. Curr Cardiol Rep. 1999 Sep; 1(3):238-43.
Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol. 1997 Nov 06; 80(9A):11I-16I.
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.